{"protocolSection": {"identificationModule": {"nctId": "NCT03267576", "orgStudyIdInfo": {"id": "CR108346"}, "secondaryIdInfos": [{"id": "28431754DIA4026", "type": "OTHER", "domain": "Janssen Research & Development, LLC"}], "organization": {"fullName": "Janssen Research & Development, LLC", "class": "INDUSTRY"}, "briefTitle": "An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin", "officialTitle": "Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin", "acronym": "COMETA"}, "statusModule": {"statusVerifiedDate": "2019-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-10-27", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-10-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-10-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-08-29", "studyFirstSubmitQcDate": "2017-08-29", "studyFirstPostDateStruct": {"date": "2017-08-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2019-09-27", "resultsFirstSubmitQcDate": "2019-11-11", "resultsFirstPostDateStruct": {"date": "2019-11-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-11-11", "lastUpdatePostDateStruct": {"date": "2019-11-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Janssen Research & Development, LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient glycemic coefficient of variation (CV), expressed as a ratio percentage of standard deviation (SD) to mean glucose levels."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 64, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment Sequence AB", "type": "EXPERIMENTAL", "description": "Participants will receive metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.", "interventionNames": ["Drug: Canagliflozin 300 mg", "Drug: Sitagliptin 100 mg", "Drug: Metformin"]}, {"label": "Treatment Sequence BA", "type": "EXPERIMENTAL", "description": "Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.", "interventionNames": ["Drug: Canagliflozin 300 mg", "Drug: Sitagliptin 100 mg", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Canagliflozin 300 mg", "description": "Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.", "armGroupLabels": ["Treatment Sequence AB", "Treatment Sequence BA"], "otherNames": ["JNJ-28431754"]}, {"type": "DRUG", "name": "Sitagliptin 100 mg", "description": "Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.", "armGroupLabels": ["Treatment Sequence AB", "Treatment Sequence BA"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants will receive metformin at a stable dose of \\>= 1500 mg/day throughout the study including the washout period between each intervention.", "armGroupLabels": ["Treatment Sequence AB", "Treatment Sequence BA"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1", "description": "Continuous blood glucose monitoring was done in participants using continuous glucose monitoring (CGM) determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and after each active treatment. Glucose coefficient of variation (CV) was calculated based on CGM data dividing the standard deviation of blood glucose values by the mean of the corresponding glucose readings. The participants were analyzed according to treatment received in treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27)"}, {"measure": "Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2", "description": "Continuous blood glucose monitoring was done in participants using CGM determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and after each active treatment. Glucose coefficient of variation was calculated based on CGM data dividing the standard deviation of blood glucose values by the mean of the corresponding glucose readings. The participants were analyzed according to treatment received in treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 2 (Days 66 to 71)"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycemic Standard Deviation (SD) for 24-hour Glucose Profile", "description": "Glycemic standard deviation for 24-hour glucose profile (glycemic variability), as measured by CGM was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants who received the study drug in the treatment period 1 and 2 as per the sequence were reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Mean 24-hour Glucose Profile", "description": "Mean 24-hour glucose profiles as measured by CGM was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Fasting Plasma Glucose Levels", "description": "Fasting plasma glucose levels were determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in 2-hour Post-prandial Glucose (PPG) Levels", "description": "2-hour post-prandial glucose levels were determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Percent Change From Baseline in Time During 24 Hours With Glucose 70 to 139 mg/dL", "description": "Percent change from baseline in time during 24 hours with glucose levels 70 to 139 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Percent Change From Baseline in Time During 24 Hours With Glucose Greater Than (>) 140 mg/dL", "description": "Percent change from baseline in time during 24 hours within the glucose levels \\>140 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Percent Change From Baseline in Time During 24 Hours With Glucose Level > 180 mg/dL", "description": "Percent change from baseline in time during 24 hours within the glucose levels \\>180 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Percent Change From Baseline in Time During 24 Hours With Glucose Level Less Than (<) 70 mg/dL", "description": "Percent change from baseline in time during 24 hours within the glucose levels \\< 70 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Time Spent With Glucose Level 70 to 139 mg/dL", "description": "Time spent with the glucose level 70 to 139 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Time Spent With Glucose Level > 140 mg/dL", "description": "Time spent with the glucose level \\> 140 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Time Spent With Glucose Level > 180 mg/dL", "description": "Time spent with the glucose level \\> 180 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Time Spent With Glucose Level < 70 mg/dL", "description": "Time spent with the glucose level \\< 70 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}, {"measure": "Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL", "description": "The percentage of 2 consecutive glucose readings with \\< 70 mg/dL were reported. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Inadequate glucose control while using metformin monotherapy (MET) for at least 8 weeks at stable daily doses of at least 1500 milligram (mg) before screening visit (Visit 1)\n\n  a. Hemoglobin A1c (HbA1c) equal to (=) 7.5 percent (%) to 10.5% at Visit 1\n* Adequate qualifying continuous glucose monitoring (CGM) reading during the pre-randomization (selection) phase\n* Estimated glomerular filtration rate (eGFR) of at least 60 milliliter/minute (mL/min)/1.73 meter square (m\\^2) at Visit 1\n* Body mass index of 22 through 45 kilogram per meter square (kg/m\\^2) at Visit 1\n\nExclusion Criteria:\n\n* History of any of the following (at Visit 1):\n\n  1. Diabetic ketoacidosis (DKA)\n  2. Type 1 diabetes mellitus (T1DM)\n  3. Pancreatic (for example, Beta-islet cell) transplantation\n  4. Diabetes secondary to pancreatitis or pancreatectomy\n  5. Personal history of, or ongoing, pancreatitis\n  6. One or more episodes of severe hypoglycemia (requiring assistance from others), as documented in the history obtained at Visit 1\n  7. Hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Repeated fasting plasma glucose (FPG) or fasting self-monitored blood glucose (SMBG) greater than (\\>) 270 milligram per deciliter (mg/dL) during the pre-treatment phase\n* Treatment with any other oral or parenteral antidiabetic medications different from metformin monotherapy, including but not limited to Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sulphonylureas, thiazolidinediones, insulins and Glucagon-like peptide-1 receptor agonist (GLP-1RAs); Sodium-glucose co-transporter 2 (SGLT-2) inhibitors and investigational agents\n* Received an investigational drug or vaccine or used an invasive investigational medical device within 30 days before the planned first dose of study drug\n* Current use of \"natural medicines\" or natural medicinal products for diabetes (for example, cactus-derived nutrients, celery)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "19 Years", "maximumAge": "54 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Janssen Research & Development, LLC Clinical Trial", "affiliation": "Janssen Research & Development, LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Consultorio Privado", "city": "Guadalajara", "zip": "44150", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigaci\u00f3n Cl\u00ednica Especializada", "city": "Guadalajara", "zip": "44600", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Consultorio Privado en Unidad de Patolog\u00eda Cl\u00ednica", "city": "Guadalajara", "zip": "44650", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Instituto Nacional de Ciencias Medicas y Nutrici\u00f3n Salvador Zubir\u00e1n", "city": "Mexico City", "zip": "14080", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Hospital Universitario 'Dr. Jose Eleuterio Gonzalez'", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 64 participants were enrolled in this study but 1 participant has withdrawn consent before assigning to any study treatment hence, 63 participants were randomized to study treatment arms.", "groups": [{"id": "FG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of at least 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "FG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "periods": [{"title": "Period 1: Day 0 to 27", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Period: 16 Days", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2: Day 44 to 71", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent-to-treat (ITT) analysis set included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful (greater than \\[\\>\\] 70 percent (%) of tracings available).", "groups": [{"id": "BG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of at 16 days (from Days 28 to 43) along with continued metformin monotherapy."}, {"id": "BG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "63"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.03", "spread": "6.237"}, {"groupId": "BG001", "value": "44.84", "spread": "9.088"}, {"groupId": "BG002", "value": "45.3", "spread": "7.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "28"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "35"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic Mexican mestizo", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "63"}]}, {"title": "Caucasian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Afro-American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Meter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.63", "spread": "0.10"}, {"groupId": "BG001", "value": "1.64", "spread": "0.10"}, {"groupId": "BG002", "value": "1.63", "spread": "0.10"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilogram", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "84.01", "spread": "15.86"}, {"groupId": "BG001", "value": "88.96", "spread": "14.17"}, {"groupId": "BG002", "value": "86.52", "spread": "15.11"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1", "description": "Continuous blood glucose monitoring was done in participants using continuous glucose monitoring (CGM) determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and after each active treatment. Glucose coefficient of variation (CV) was calculated based on CGM data dividing the standard deviation of blood glucose values by the mean of the corresponding glucose readings. The participants were analyzed according to treatment received in treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "Intent-to-treat (ITT) analysis set included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful (greater than \\[\\>\\] 70% of tracings available).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of CV", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.69", "spread": "5.17"}, {"groupId": "OG001", "value": "0.24", "spread": "10.23"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2", "description": "Continuous blood glucose monitoring was done in participants using CGM determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and after each active treatment. Glucose coefficient of variation was calculated based on CGM data dividing the standard deviation of blood glucose values by the mean of the corresponding glucose readings. The participants were analyzed according to treatment received in treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "ITT analysis set included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful (\\>70% of tracings available).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of CV", "timeFrame": "Baseline up to End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.26", "spread": "7.41"}, {"groupId": "OG001", "value": "0.77", "spread": "6.16"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycemic Standard Deviation (SD) for 24-hour Glucose Profile", "description": "Glycemic standard deviation for 24-hour glucose profile (glycemic variability), as measured by CGM was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants who received the study drug in the treatment period 1 and 2 as per the sequence were reported in this outcome measure.", "populationDescription": "Per-protocol (PP) analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.64", "spread": "6.56"}, {"groupId": "OG001", "value": "-8.40", "spread": "11.07"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.53", "spread": "10.35"}, {"groupId": "OG001", "value": "-7.13", "spread": "12.00"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean 24-hour Glucose Profile", "description": "Mean 24-hour glucose profiles as measured by CGM was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-34.81", "spread": "34.87"}, {"groupId": "OG001", "value": "-39.56", "spread": "39.79"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.27", "spread": "33.27"}, {"groupId": "OG001", "value": "-41.74", "spread": "34.14"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose Levels", "description": "Fasting plasma glucose levels were determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.04", "spread": "33.95"}, {"groupId": "OG001", "value": "-34.48", "spread": "32.94"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.69", "spread": "32.19"}, {"groupId": "OG001", "value": "-45.51", "spread": "35.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Post-prandial Glucose (PPG) Levels", "description": "2-hour post-prandial glucose levels were determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-47.03", "spread": "45.85"}, {"groupId": "OG001", "value": "-43.36", "spread": "48.00"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-41.12", "spread": "44.77"}, {"groupId": "OG001", "value": "-44.03", "spread": "43.80"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Time During 24 Hours With Glucose 70 to 139 mg/dL", "description": "Percent change from baseline in time during 24 hours with glucose levels 70 to 139 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all intent-to-treat participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.157", "spread": "0.134"}, {"groupId": "OG001", "value": "0.191", "spread": "0.224"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.192", "spread": "0.214"}, {"groupId": "OG001", "value": "0.182", "spread": "0.209"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Time During 24 Hours With Glucose Greater Than (>) 140 mg/dL", "description": "Percent change from baseline in time during 24 hours within the glucose levels \\>140 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.161", "spread": "0.145"}, {"groupId": "OG001", "value": "-0.216", "spread": "0.257"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-214", "spread": "0.237"}, {"groupId": "OG001", "value": "-0.221", "spread": "0.210"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Time During 24 Hours With Glucose Level > 180 mg/dL", "description": "Percent change from baseline in time during 24 hours within the glucose levels \\>180 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.235", "spread": "0.204"}, {"groupId": "OG001", "value": "-0.212", "spread": "0.286"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.246", "spread": "0.232"}, {"groupId": "OG001", "value": "-0.251", "spread": "0.249"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Time During 24 Hours With Glucose Level Less Than (<) 70 mg/dL", "description": "Percent change from baseline in time during 24 hours within the glucose levels \\< 70 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Time Spent With Glucose Level 70 to 139 mg/dL", "description": "Time spent with the glucose level 70 to 139 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Minutes", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "226.64", "spread": "193.01"}, {"groupId": "OG001", "value": "275.64", "spread": "323.39"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "277.00", "spread": "309.46"}, {"groupId": "OG001", "value": "261.57", "spread": "301.75"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Time Spent With Glucose Level > 140 mg/dL", "description": "Time spent with the glucose level \\> 140 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Minutes", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-231.98", "spread": "208.27"}, {"groupId": "OG001", "value": "-310.41", "spread": "370.20"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-308.68", "spread": "341.00"}, {"groupId": "OG001", "value": "318.23", "spread": "303.02"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Time Spent With Glucose Level > 180 mg/dL", "description": "Time spent with the glucose level \\> 180 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Minutes", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-338.36", "spread": "293.40"}, {"groupId": "OG001", "value": "-305.69", "spread": "412.30"}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-354.63", "spread": "333.52"}, {"groupId": "OG001", "value": "-361.65", "spread": "358.27"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Time Spent With Glucose Level < 70 mg/dL", "description": "Time spent with the glucose level \\< 70 mg/dL was determined over a 6-day period (in order to obtain a continuous 72-hour reading) at baseline and at the end of each active treatment. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Minutes", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL", "description": "The percentage of 2 consecutive glucose readings with \\< 70 mg/dL were reported. The participants were analyzed according to treatment received in treatment period 1 and treatment period 2 as per the sequence reported in this outcome measure.", "populationDescription": "PP analysis set included all ITT participants without a major protocol violation, where ITT population included all participants who received at least one dose of medication and in whom CGM recordings at baseline and after each active treatment were successful.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of readings", "timeFrame": "Baseline up to End of Treatment Period 1 (Days 22 to 27) and End of Treatment Period 2 (Days 66 to 71)", "groups": [{"id": "OG000", "title": "Treatment Sequence AB", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin \\>=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from Days 28 to 43) along with ongoing metformin monotherapy."}, {"id": "OG001", "title": "Treatment Sequence BA", "description": "Participants received metformin monotherapy at stable doses \\>=1500 mg/day with sitagliptin 100 mg tablet orally once daily (Treatment B) from Day 0 to 27 (treatment Period 1), followed by metformin \\>= 1500 mg/day orally once daily with canagliflozin 300 mg tablet orally once daily (Treatment A) from Day 44 to 71 (treatment period 2), under fasted condition with a washout period of 16 days (from days 28 to 43) along with ongoing metformin monotherapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Treatment Period 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}]}]}, {"title": "Treatment Period 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Here, NA signifies that data could not be calculated since there were \\<5 cases with valid observations of glycemic readings \\<70 mg/dL."}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Up to 96 Days", "description": "Adverse events (AEs) reported are when they occurred under the actual treatment group they were receiving at the AE and not by the randomized sequence. Safety population included all randomized participants who received at least 1 dose of study agent.", "eventGroups": [{"id": "EG000", "title": "Canagliflozin 300 mg", "description": "Participants received metformin monotherapy at stable doses (greater than or equal to \\[\\>=\\] 1500 milligram per day \\[mg/day\\]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) under fasted condition.", "deathsNumAffected": 0, "deathsNumAtRisk": 63, "seriousNumAffected": 0, "seriousNumAtRisk": 63, "otherNumAffected": 7, "otherNumAtRisk": 63}, {"id": "EG001", "title": "Sitagliptin 100 mg", "description": "Participants received metformin monotherapy at stable doses \\>= 1500 milligram mg/day orally once daily with sitagliptin 100 mg tablet orally once daily (Treatment B) under fasted condition.", "deathsNumAffected": 0, "deathsNumAtRisk": 63, "seriousNumAffected": 0, "seriousNumAtRisk": 63, "otherNumAffected": 2, "otherNumAtRisk": 63}], "otherEvents": [{"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 63}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 63}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 63}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 63}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The main limitation of the study was the sample size limited to demonstrate any significant difference."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."}, "pointOfContact": {"title": "Senior Director", "organization": "Janssen Research & Development, LLC", "email": "ClinicalTrialDisclosure@its.jnj.com", "phone": "844-434-4210"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-07-31", "uploadDate": "2019-09-27T08:29", "filename": "Prot_000.pdf", "size": 3762680}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-08-13", "uploadDate": "2019-09-27T08:29", "filename": "SAP_001.pdf", "size": 674887}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000068896", "term": "Canagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M331", "name": "Canagliflozin", "asFound": "Nasopharyngeal", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}